IPP Bureau
Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
By IPP Bureau - May 30, 2026
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
Merck’s experimental cancer drug wins FDA breakthrough status in key lung cancer setting
By IPP Bureau - May 30, 2026
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
Glenmark posts strong FY26 results with 27.5% revenue jump
By IPP Bureau - May 30, 2026
Lupin wins FDA nod for generic colonoscopy prep drug with first-to-file exclusivity
By IPP Bureau - May 30, 2026
Crucially, Lupin is the exclusive first-to-file applicant for this product and is eligible for 180-day generic drug exclusivity in the U.S. market
AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial
By IPP Bureau - May 30, 2026
The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis
FDA greenlights AstraZeneca’s Imfinzi combo in bladder cancer breakthrough
By IPP Bureau - May 30, 2026
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
FDA delays AstraZeneca decision on camizestrant as regulators seek more data
By IPP Bureau - May 30, 2026
The filing is backed by results from the pivotal SERENA-6 Phase III trial
Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%
By IPP Bureau - May 29, 2026
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
Supreme Court declares right to trauma care part of Article 21 in landmark judgement
By IPP Bureau - May 29, 2026
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial
By IPP Bureau - May 29, 2026
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Abbott secures CE mark for first dual glucose-ketone monitoring systems
By IPP Bureau - May 29, 2026
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
Solvay and Pantys deepen partnership to expand menstrual health access
By IPP Bureau - May 29, 2026
Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs
Eli Lilly secures full PBM coverage for obesity drug portfolio expanding access to millions
By IPP Bureau - May 29, 2026
The move marks one of the most significant coverage expansions yet in obesity care, bringing FDA-approved treatment options further into mainstream insurance plans rather than out-of-pocket reach
AbbVie wins FDA nod for DECNUPAZ in rare blood cancer
By IPP Bureau - May 29, 2026
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Indian scientists develop AI-enabled tech for biomedical diagnostic applications
By IPP Bureau - May 28, 2026
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
